<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Our primary clinical outcome data was development of low cardiac output syndrome (LCOS) as defined by at least one of the following during the first 48 h period: VIS &gt; 15 at any time, addition of a new vasoactive agent for patients already on inotropic or vasopressor support or a new initiation of vasoactive support (inotropes or vasopressors or milrinone) after a 24 h period with no support.</p>
